Fixed-duration venetoclax plus obinutuzumab improves quality of life and geriatric impairments in FCR-unfit patients with CLL
Lina van der Straten(Erasmus MC), Mark‐David Levin(Albert Schweitzer Ziekenhuis), H.C.T. van Zaanen(Sint Franciscus Gasthuis), Sanne H. Tonino(Amsterdam UMC Location University of Amsterdam), Ilse Houtenbos(Spaarne Ziekenhuis), Peter E. Westerweel(Cornell University), Michel van Gelder(Maastricht University), Eduardus F. M. Posthuma(Leiden University Medical Center), Anne-Marie Van Der Kevie-Kersemaekers, Mels Hoogendoorn(Medisch Centrum Leeuwarden), Clemens Mellink, Claudia A.M. Stege(Amsterdam University Medical Centers), Cecile Idink, Ellen van der Spek(Rijnstate Hospital), Marjolein van der Klift(Amphia Ziekenhuis), Sabina Kersting(Haga Hospital), Kazem Nasserinejad(Erasmus MC Cancer Institute), John Schreurs(Martini Ziekenhuis), Lidwine W. Tick(Radboud University Nijmegen), Hendrik Veelken(University of Freiburg), Henriëtte Levenga(Groene Hart Ziekenhuis), Arnon P. Kater(Sanford Burnham Prebys Medical Discovery Institute), Gerjo A. Velders(Ziekenhuis Gelderse Vallei), Hanneke M. Straaten(Rijnstate Hospital), Hein P. J. Visser(Northwest Hospital), Ellen C. Dompeling(Isala), Wim Terpstra(OLVG), Anton W. Langerak(Erasmus MC), Fransien de Boer(Ikazia Ziekenhuis), Djamila E. Issa(Jeroen Bosch Ziekenhuis), Harry R. Koene(St. Antonius Ziekenhuis), Johan A. Dobber(Amsterdam University Medical Centers), Ludo M. Evers(Amsterdam University Medical Centers), Julie Dubois(Amsterdam University Medical Centers)
Cited by 27
Related Papers
Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2018|907
Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial
|Journal of Clinical Oncology|2021|630
Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2020|568
Essential role of stromally induced hedgehog signaling in B-cell malignancies
|Nature Medicine|2007|321